The Department of Health and Human Services recently canceled $500 million in funding for vaccine research that it had previously pledged to scientists. Obviously, the broken promise is a ...
If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...
Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink. In this episode, Fierce Biotech’s Darren Incorvaia and Gabrielle Masson came ...
Commentary: Biotechnology lets scientists engineer natural ingredients into products, often more sustainably than if they were farmed. Here's what to know. Deenie is a CNET Perspectives contributor ...
Few neighborhoods in Cambridge have seen their fortunes change as dramatically as Kendall Square. Kendall was once known for churning out soap and vulcanized rubber, then manufacturing electronics as ...
In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...
Something unusual is happening to biotech stocks: They’re going up. A drug-pricing deal between Pfizer and the White House and a spate of deals have sent the SPDR S&P Biotech exchange-traded fund up 9 ...
After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus. The question is whether this rally marks a real recovery or just another ...
China’s biotech sector is surging. For the first time, it now leads the world in clinical trials and new drug licensing. The U.S., once the undisputed leader in pharmaceutical innovation, risks losing ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
‘Disheartening? Yes. Surprising? No.’ Report on the future of biotech in Mass. gives a grim outlook.
The industry group MassBio released its annual temperature check on the state’s biotech industry Tuesday, and the results are grim. Both public and private funding have plummeted as federal policy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback